Patent EP0255002A1 successfully refreshed from Google Patents.
EP0255002A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
New pharmaceutical formulations with programmed release containing antiphlogistics
Assignee: Alfa Wasserman SpA
•
Filing: 1987-07-17
•
Granted: —
•
Expires: 2007-07-17
Abstract
Abstract New galenic formulations with programmed release, to be administered by oral route, containing as the active ingredient a compound endowed with antiphlogistic, analgesic and antipyretic activity like, for instance, an arylacetic or an arylpropionic acid and the pharmaceutically acceptable salts thereof. In these new formulations, a portion of the active ingredient is released in a short time, so that the drug can quickly develop its therapeutic action reaching the necessary hematic levels, while the remaining portion of the active constituent is released in a longer interval of time so as to allow the therapeutic coverage till the subsequent administration. Said therapeutic coverage can even last 24 hours; thus the new galenic formulations object of the present invention are suitable for a once a day administration.
Inventors
- 👤 Leone Gabriele Rotini
- 👤 Egidio Marchi
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 19:11
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K9/00; A61K9/20; A61K9/2072; A61K9/2077; A61K9/48; A61K9/50; A61K9/5084; A61P; A61P25/00; A61P25/04; A61P29/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
85 words
Process for the production of a galenic formulation for oral use with programmed release containing as the active principle a compound endowed with antiinflammatory, analgesic and antipyretic activity, characterized by mixing a granulate having immediate release containing from about 30% to about 70% of the whole amount of the active principle in admixture with binding, disintegrating and lubricating agents, and a granulate having controlled release containing from about 30% to about 70% of the whole amount of the active principle in admixture with retarding agents.
Claim 2
Dependent Claim
85 words
Process for the production of a galenic formulation for oral use with programmed release containing as the active principle a compound endowed with antiinflammatory, analgesic and antipyretic activity, characterized by mixing a granulate having immediate release containing from about 30% to about 70% of the whole amount of the active principle in admixture with binding, disintegrating and lubricating agents, and a granulate having controlled release containing from about 30% to about 70% of the whole amount of the active principle in admixture with retarding agents.
Claim 3
Dependent Claim
36 words
Process according to claim 1, characterized in that the active principles having antiinflammatory, analgesic and antipyretic activity are arylacetic and arylpropionic acids both as free acids and as pharmaceutically acceptable salts with organic or inorganic bases.
Claim 4
Dependent Claim
29 words
Process according to claim 2, characterized in that the active principles having antiinflammatory, analgesic and antipyretic activity are selected from naproxen, ibuprofen, flurbiprofen, ketoprofen, fenoprofen, indomethacin, diclofenac and fentiazac.
Claim 5
Dependent Claim
23 words
Process according to claim 3 wherein the active principles having antiinflammatory, analgesic and antipyretic activity are selected from naproxen, ibuprofen, ketoprofen and diclofenac.
Claim 6
Dependent Claim
52 words
Process according to claim 1 wherein the binding agents are selected from polyvinylpyrrolidone, carboxymethylcellulose, microcrystalline cellulose, lactose, saccharose, mannitol, arabic gum, pectin and gelatin, the disintegrating agents are selected from starchs, alginates, sodium starch glycolate and reticulated polyvinylpyrrolidone, the lubricating agents are selected from magnesium stearate, talc, stearic acid and silica gel.
Claim 7
Dependent Claim
73 words
Process according to claim 1 wherein in the granulate having controlled release the retarding agents are selected from ethylcellulose, methylcellulose, polyvinylacetate, metacrylic acid esters, cellulose acetate, fatty alcohols containing from 10 to 22 carbon atoms, esters of fatty acids and alcohols having from 21 to 31 carbon atoms, paraffin, beeswax, unbleached wax, candelilla wax, carnauba wax, sealing wax, spermaceti, ozokerite, hydrogenated castor oil, hydrogenated peanut oil, hydrogenated cotton seed oil and mixtures thereof.
Claim 8
Dependent Claim
20 words
Process according to claim 6 wherein the retarding agents are selected from methylcellulose, ethylcellulose, hydrogenated vegetable oils and mixtures thereof.
Claim 9
Dependent Claim
42 words
Process according to claim 1 wherein the granulate having immediate release contains from 60% to 70% of the active principle, from 20% to 30% of binding agents, from 8% to 12% of disintegrating agents and from 0.2% to 1% of lubricating agents.
Claim 10
Dependent Claim
36 words
Process according to claim 1 wherein the granulate having controlled release contains from 60% to 70% of the active principle and from 30% to 40% of a retarding agent or of a mixture of retarding agents.
Claim 11
Dependent Claim
15 words
Process according to claim 9 wherein the retarding agents are defined as in claim 7.
References Cited (Backward Citations)
FR1159165A
Cited
BE658905A
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.